[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571566":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":59,"collaborators":25,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":44,"whyStopped":25,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of British Columbia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Continuous protein","ACTIVE_COMPARATOR","Continuous protein arm will have dietary protein supplement mixed into the enteral formula product to be provided around the clock without break.",[13],"Dietary Supplement: Dietary protein",{"label":15,"type":16,"description":17,"interventionNames":18},"Bolus protein","EXPERIMENTAL","Bolus protein arm will provide protein powder mixed with water every 4h through syringe. This will be in addition to continuous enteral formula feeding which remains standard of care.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Dietary protein","Beneprotein powder, a whey-based supplement, will be used in both arms. Intervention dose will be 1g\u002Fkg of dietary protein (or 1.2g\u002Fkg of the powder), provided to both arms with different modes of delivery.",[15,9],null,[27],{"name":28,"affiliation":29,"role":30},"Rajavel Elango, PhD","University of British Columbia, Department of Pediatrics","PRINCIPAL_INVESTIGATOR",[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Kaitlin A Berris, BSc","CONTACT","604-875-2000","1445","kaitlin.berris@bcchr.ca",{"name":28,"role":34,"phone":35,"phoneExt":39,"email":40},"4911","relango@bcchr.ubc.ca",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"BC Childrens Hospital","RECRUITING","Vancouver","British Columbia","V6H 3N1","Canada","CA",{"type":51,"coordinates":52},"Point",[53,54],-123.11934,49.24966,{"lat":54,"lon":53},[57,58],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},{"name":28,"role":30,"phone":25,"phoneExt":25,"email":25},{"type":30,"investigatorFullName":28,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Professor","100571566","continuous-vs-bolus-protein-protein-regimen-outcomes-in-critically-ill-children-kids-in-distress-100571566",false,"NCT06721923","Continuous vs Bolus Protein (Protein Regimen Outcomes) in Critically Ill Children (Kids In Distress)","Continuous Versus Bolus Dietary Protein and Nutrition Status in the Pediatric Intensive Care Unit: Pilot Study","PRO-KID","Inclusion Criteria:\n\n* Children admitted to PICU over 1 year of age and younger than 11 years of life\n* Expected to remain in the pediatric intensive care unit for longer than 72 hours\n* Receiving standard pediatric formula via NGT\u002FOGT\u002FGT\n\nExclusion Criteria:\n\n* Neuromuscular condition such as muscular dystrophy\n* Admitted with home prescription for high dose steroids, receives growth hormone or insulin\n* Enteral nutrition is contraindicated or if nutrition requirements are partially\u002Ffully met by parenteral nutrition\n* Formula delivered into the small bowel (duodenum\u002Fjejunum, NJT\u002FGJ)\n* Those who require a highly specialized diet (E.g., large burns or metabolic diseases)\n* Patients with a cow's milk protein allergy cannot safely receive a whey-based protein supplement","ALL","1 Year","11 Years",{"count":73,"type":74},96,"ESTIMATED","INTERVENTIONAL",[77],"NA","The goal of this intervention study is to evaluate the difference in nutrition status markers (weight and muscle mass) when giving dietary protein by continuous or bolus delivery in critically ill children ages 1-11y.\n\nThe main questions it aims to answer are:\n\nPrimary: Bolus protein delivery will lessen the decline in mid-upper arm circumference (MUAC) z-score by 0.5 standard deviation in critically ill children aged 1-11y after 1wk. Ultrasound will correlate to MUAC.\n\nSecondary: Bolus protein delivery will provide more (grams per day) than when provided continuously, therefore it is more likely to meet the minimum estimated needs.\n\nParticipants will have daily nutrition intake data collected, and undergo body composition measures (weight, MUAC and ultrasound of the upper thigh muscle) at day of enrollment, and MUAC\u002FUltrasound on follow up days 3, 5, 7 and 14 after the intervention started.",[80,81,82,83],"Critical Illness","Pediatric Intensive Care","Enteral Nutrition Therapy","Dietary Protein",[85,86,87,88,89,90],"enteral nutrition","pediatric critical care","bolus protein delivery","continuous protein delivery","ultrasound","mid-upper arm circumference","2026-02-09",{"date":93,"type":94},"2026-02-12","ACTUAL",{"date":96,"type":94},"2024-02-13",{"date":98,"type":74},"2027-12-12",{"name":5,"class":6},1]